nach oben

Erschienen in:

29.07.2020 | Leitlinien, Stellungnahmen und Empfehlungen

Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration

Status February 2020

verfasst von: German Society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, DOG), German Retina Society (Retinologische Gesellschaft e. V., RG), Professional Association of German Ophthalmologists (Berufsverband der Augenärzte Deutschlands e. V., BVA)

Erschienen in: Die Ophthalmologie | Sonderheft 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Intravitreal anti-VEGF therapy is the established standard of care for neovascular age-related macular degeneration (nAMD) [1‐12]. In the light of new results on therapeutic strategies and novel drugs, an update of the statement on anti-VEGF treatment of nAMD in Germany is appropriate. The following core statements are presented and elaborated in more detail in the subsequent long-text version. …

Nur mit Berechtigung zugänglich

RG, DOG, BVA (2007) Aktuelle therapeutische Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration.Stellungnahme der RG, der DOG und des BVA zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 104:628–634

RG, DOG, BVA (2007) Stellungnahme der RG, der DOG und des BVA zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monbl Augenheilkd 224:559–566

RG, DOG, BVA (2009) Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration. Stellungnahme der RG, der DOG und des BVA. Ophthalmologe 106:457–464

RG, DOG, BVA (2009) Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration. Stellungnahme der RG, der DOG und des BVA. Klin Monbl Augenheilkd 226:388–395

RG, DOG, BVA (2011) Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration: Kriterien der Wiederbehandlung bei der Anti- VEGF Therapie. Ergänzende Stellungnahme der RG, der DOG und des BVA. Ophthalmologe 1:86–90

RG, DOG, BVA (2012) Aktuelle Stellungnahme der RG, der DOG und des BVA. Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: therapeutische Strategien. Klin Monatsbl Augenheilkd 229:541–547

RG, DOG, BVA (2012) Die Anti-VEGF-Therapie bei der neovaskulären alterabhängigen Makuladegeneration: Therapeutische Strategien. Aktuelle Stellungnahme der RG, der DOG und des BVA. Ophthalmologe 109:405–414

RG, DOG, BVA (2013) Aktuelle Stellungnahme der RG, der DOG und des BVA. Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: therapeutische Strategien – Status Dezember 2012. Klin Monbl Augenheilkd 230:170–177

10.

RG, DOG, BVA (2013) Die Anti-VEGF-Therapie bei der neovaskulären alterabhängigen Makuladegeneration: Therapeutische Strategien – Status Dezember 2012. Aktuelle Stellungnahme der RG, der DOG und des BVA. Ophthalmologe 110:405–411

11.

RG, DOG, BVA (2015) Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: Therapeutische Strategien; Stand November 2014. Aktuelle Stellungnahme der RG, der DOG und des BVA. Klin Monatsbl Augenheilkd 232:202–210

12.

13.

Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444PubMed

14.

Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116:57–65PubMed

15.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548PubMed

16.

Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121:193–201PubMed

17.

Dugel PH, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger AA, Holz FG (2020) HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72–84PubMed

18.

CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908

19.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398

20.

IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411

21.

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2‑year findings of the IVAN randomised controlled trial. Lancet 382(9900):1258–1267PubMed

22.

Abedi F, Wickremasinghe S, Islam AF, Inglis KM, Guymer RH (2014) Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina 34:1531–1538PubMed

23.

Berg K, Pedersen TR, Sandvik L, Bragadóttir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152PubMed

24.

Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, Morlet N, Hunyor AP, Essex RW, Arnold JJ, Gillies MC (2018) “Treat and Extend” Intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina 38:20–28PubMed

25.

Matsumoto H, Morimoto M, Mimura K, Ito A, Akiyama H (2018) Treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration: efficacy and macular atrophy development. Ophthalmol Retina 2:462–468PubMed

26.

Augsburger M, Sarra GM, Imesch P (2019) Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol 257:1889–1895PubMed

27.

Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL (2019) Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol 137:372–379PubMedPubMedCentral

28.

Kertes PJ, Galic IJ, Greve M, Williams RG, Rampakakis E, Scarino A, Sheidow T (2019) Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian treat-and-extend analysis trial with ranibizumab study. Ophthalmology 126:841–848PubMed

29.

Traine PG, Pfister IB, Zandi S, Spindler J, Garweg JG (2019) Long-term outcome of Intravitreal aflibercept treatment for neovascular age-related macular degeneration using a “treat-and-extend” regimen. Ophthalmol Retina 3:393–399PubMed

30.

Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98:1144–1167PubMed

31.

Gale RP, Mahmood S, Devonport H, Patel PJ, Ross AH, Walters G, Downey L, El-Sherbiny S, Freeman M, Berry S, Jain N (2019) Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye 33:1–21PubMedPubMedCentral

32.

BVA, DOG, RG (2018) Zentrale Aspekte zur Durchführung und Indikationsstellung der IVOM. Kurzstellungnahme von BVA, DOG und RG. Stand Juni 2017. Augenarzt 2:83

33.

BVA, DOG, RG (2017) Stellungnahme des BVA, DOG und RG. Qualitätssicherung der optischen Kohärenztomografie für die Diagnostik des Augenhintergrunds. Stand März 2017. Klin Monatsbl Augenheilkd 234:650–662

34.

BVA, DOG, RG (2017) Stellungnahme des BVA, DOG und RG. Qualitätssicherung der optischen Kohärenztomografie für die Diagnostik des Augenhintergrunds. Stand März 2017. Ophthalmologe 114:220–226

35.

BVA, DOG, RG (2017) Stellungnahme des BVA, der DOG und der RG: OCT-Angiographie in Deutschland. Präsentation, Nomenklatur und Zukunftswünsche. Stand Januar 2017. Klin Monatsbl Augenheilkd 234:829–840

36.

BVA, DOG, RG (2017) Stellungnahme des BVA, der DOG und der RG: OCT-Angiographie in Deutschland. Präsentation, Nomenklatur und Zukunftswünsche. Stand Januar 2017. Ophthalmologe 114:432–438

37.

Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John VJ, Rich RM, Chaudhry N, Lakhanpal RR, Oellers PR, Leveque TK, Chittum ME, Gonzalez AE, Bacci T, Rutledge B, Sund NJ, Subong EN, Albini TA (2020) Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology [Epub ahead of print]

38.

Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D’Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G (2014) Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 9:CD11230. https://doi.org/10.1002/14651858.CD011230.pub2CrossRef

39.

Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292–2299PubMed

40.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:1751–1761

41.

Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P (2014) Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121:2181–2192PubMed

42.

Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y (2020) Efficacy and safety of Intravitreal aflibercept treat- and -extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR. A randomized controlled trial. Adv Ther. https://doi.org/10.1007/s12325-020-01236-xCrossRefPubMedPubMedCentral

43.

Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220–226PubMed

44.

Wolf A, Kampik A (2014) Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol 252:647–655PubMedPubMedCentral

45.

Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG (2013) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study—a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91:540–546PubMed

46.

Stasch-Bouws J, Eller-Woywod SM, Schmickler S, Inderfurth J, Hoffmann P, Ohlmeyer C, Kammering B, Pauleikhoff D (2020) Intravitreale operative Medikamenteneingabe (IVOM) – Qualitätssicherung in Westfalen-Lippe. Aufbau der Qualitätssicherung und Ergebnisse der Pilotstudie Q‑VERA. Ophthalmologe. https://doi.org/10.1007/s00347-019-01030-3CrossRefPubMed

47.

Mantel I, Niderprim S‑A, Gianniou C, Deli A, Ambresin A (2014) Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol 98:1192–1196PubMed

48.

Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, Ambresin A, Mantel I (2015) Two-year outcome of an observe & plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye 29:342–349PubMed

49.

Parvin P, Zola M, Dirani A, Ambresin A, Mantel I (2017) Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with aflibercept. Graefes Arch Clin Exp Ophthalmol 255:2127–2134PubMedPubMedCentral

50.

Heimes B, Lommatzsch A, Zeimer M et al (2011) Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol 249:639–644PubMed

51.

Hoerster R, Muether PS, Hermann MM, Koch K, Kirchhof B, Fauser S (2011) Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography. Br J Ophthalmol 95:1424–1426PubMed

52.

Lim JH, Wickremasinghe SS, Xie J et al (2012) Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 153:678–686PubMedPubMedCentral

53.

Jang L, Gianniou C, Ambresin A, Mantel I (2015) Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. Graefes Arch Clin Exp Ophthalmol 253:1211–1216PubMed

54.

Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ (2019) Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology 126:723–734PubMed

Titel: Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration
Status February 2020
verfasst von: German Society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, DOG)
German Retina Society (Retinologische Gesellschaft e. V., RG)
Professional Association of German Ophthalmologists (Berufsverband der Augenärzte Deutschlands e. V., BVA)
Publikationsdatum: 29.07.2020
Verlag: Springer Medizin
Erschienen in: Die Ophthalmologie / Ausgabe Sonderheft 1/2021
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-020-01188-1

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration

Status February 2020

Excerpt

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2021

Can SARS-CoV-2 infect the eye? An overview of the receptor status in ocular tissue

Erratum zu: Bewertung von Risikofaktoren für das Auftreten des Offenwinkelglaukoms

Statement of the German Society of Ophthalmology, the German Retina Society, and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity

Evaluation of patient satisfaction with an ophthalmology video consultation during the COVID-19 pandemic

What is the significance of the conjunctiva as a potential transmission route for SARS-CoV-2 infections?

Leitlinie Nr. 24a Uveitis intermedia

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde